Lead Product(s) : Divalproex Sodium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-711 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2025
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-142
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-142 is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 17, 2025
Lead Product(s) : ABBV-142
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-547
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-547 is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 17, 2025
Lead Product(s) : ABBV-547
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onabotulinumtoxin A
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGN-151607-DP (onabotulinumtoxin A) is a protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hernia, Ventral.
Product Name : AGN-151607-DP
Product Type : Protein
Upfront Cash : Inapplicable
November 10, 2025
Lead Product(s) : Onabotulinumtoxin A
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAR445399
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR445399 is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 06, 2025
Lead Product(s) : SAR445399
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-1042
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ABBV-1042 Movement and Adverse Event Study in Healthy Adult Participants
Details : ABBV-1042 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2025
Lead Product(s) : ABBV-1042
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Everolimus
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Breckenridge Launches Generic Everolimus Tablets, 1mg
Details : Everolimus, a miscellaneous product targeting FK506-binding protein 1A, shows promise in treating organ rejection in adult patients undergoing kidney and liver transplantation.
Product Name : Zortress-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2025
Lead Product(s) : Everolimus
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Yellow Fever Vaccine (Live)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Single Arm, Open Study on vYF in Adults
Details : Yellow Fever Vaccine (Live) is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Yellow Fever.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 29, 2025
Lead Product(s) : Yellow Fever Vaccine (Live)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Balinatunfib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Balinatunfib Long-Term Study in Crohn’s and Ulcerative Colitis Patients
Details : Balinatunfib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2025
Lead Product(s) : Balinatunfib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Adverse Events of ABBV-932 in Bipolar Depressive Episode Patients
Details : ABBV-932 is a small molecule candidate which is currently being evaluated in Phase II clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2025
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
